Koers Sinopharm Group Co., Ltd. Shanghai - Hong Kong Stock Connect
Aandelen
1099
CNE100000FN7
Farmaceutische producten
Omzet 2024 * | 649 mld. 89,62 mld. 701 mld. 83,65 mld. | Omzet 2025 * | 707 mld. 97,61 mld. 763 mld. 91,11 mld. | Marktkapitalisatie | 57,3 mld. 7,91 mld. 61,86 mld. 7,39 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 9,61 mld. 1,33 mld. 10,38 mld. 1,24 mld. | Nettowinst (verlies) 2025 * | 10,58 mld. 1,46 mld. 11,42 mld. 1,36 mld. | EV/omzet 2024 * | 0,11 x |
Nettoschuld 2024 * | 11,49 mld. 1,59 mld. 12,41 mld. 1,48 mld. | Nettoschuld 2025 * | 9,36 mld. 1,29 mld. 10,1 mld. 1,21 mld. | EV/omzet 2025 * | 0,09 x |
K/w-verhouding 2024 * |
5,95
x | K/w-verhouding 2025 * |
5,41
x | Werknemers | - |
Dividendrendement 2024 * |
5,09% | Dividendrendement 2025 * |
5,59% | Vrij verhandelbaar | 42,99% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yong Liu
PSD | President | 55 | 09-01-09 |
Shuang Jun Xu
PRN | Corporate Officer/Principal | 55 | 01-03-11 |
Zhong Xi Cai
PRN | Corporate Officer/Principal | 59 | 01-05-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Tak Lung Wu
BRD | Director/Board Member | 58 | 18-09-20 |
Qi Yu Chen
BRD | Director/Board Member | 52 | 01-05-10 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | 11-01-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+14,71% | 69,79 mld. | |
+1,36% | 24,85 mld. | |
+7,11% | 8,2 mld. | |
-20,55% | 7,96 mld. | |
+3,48% | 4,69 mld. | |
+17,12% | 4,32 mld. | |
-1,24% | 3,99 mld. | |
-3,16% | 3,81 mld. | |
+21,42% | 3,62 mld. |